NCT05851677Recruiting
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
Source: ClinicalTrials.gov · Last updated 17 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 30 Apr 2023
- Start date
- 1 Jun 2023
- Primary completion date
- Mar 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT05851677
What you commit to
- Study type: Observational
- Planned participants: 45
- From 1 Jun 2023 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Who the study is looking for
- Histologically confirmed breast cancer;
- Prior or current use of Disitamab vedotin (RC48-ADC);
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.